Market Place
Sourcing Support
IDEAYA Bio Announces Inducement Grants Under Nasdaq LR 5635(C)(4)
01 May 2026 //
PR NEWSWIRE
IDEAYA to file NDA for darovasertib via RTOR Program
30 Apr 2026 //
PR NEWSWIRE
IDEAYA Biosciences To Present Full Optimum-02 Trial Data
21 Apr 2026 //
PR NEWSWIRE
IDEAYA Biosciences, Servier Report Positive Phase 2/3 Trial
13 Apr 2026 //
PR NEWSWIRE
IDEAYA, Servier Advance Top Eye Cancer Drug to FDA
13 Apr 2026 //
BIOSPACE
IDEAYA and Servier`s Eye Cancer Drug Meets Trial Goal
13 Apr 2026 //
REUTERS
IDEAYA Biosciences To Release Phase 2/3 Optimum-02 Trial Results
11 Apr 2026 //
PR NEWSWIRE
IDEAYA Announces First-Patient-In for Phase 1 Trial of IDE574
06 Apr 2026 //
PR NEWSWIRE
IDEAYA Biosciences Launches Phase 1 IDE849 Combo Study
30 Mar 2026 //
PR NEWSWIRE
IDEAYA Bio Announces Inducement Grants Under Nasdaq LR 5635(C)(4)
27 Mar 2026 //
PR NEWSWIRE
IDEAYA Updates Darovasertib Data, Investor Events
22 Mar 2026 //
PR NEWSWIRE
IDEAYA Biosciences Launches Phase 1 IDE892 Trial
09 Mar 2026 //
PR NEWSWIRE
Biocytogen Doses 1st Patient in IDE034 Ph 1 Bispecific ADC Trial
27 Feb 2026 //
BUSINESSWIRE
IDEAYA Bio Announces Inducement Grants Under Nasdaq LR 5635(C)(4)
27 Feb 2026 //
PR NEWSWIRE
Matterworks Announces Update to Leadership Team
17 Feb 2026 //
PR NEWSWIRE
IDEAYA Bio Announces Inducement Grants Under Nasdaq LR 5635(C)(4)
30 Jan 2026 //
PR NEWSWIRE BIO
IDEAYA Files IDE574 IND for KAT6/7 in Breast, Lung Cancers
10 Dec 2025 //
PR NEWSWIRE
FDA Clears IND for Biocytogen`s IDE034 Bispecific ADC
04 Dec 2025 //
BUSINESSWIRE
IDEAYA Biosciences Clears IDE034, IND For Bispecific B7H3/PTK7
01 Dec 2025 //
PR NEWSWIRE
IDEAYA Ph2 Combo Shows OS Benefit in Uveal Melanoma at SMR 2025
20 Oct 2025 //
PR NEWSWIRE
IDEAYA Biosciences Reveals Positive Phase 2 Results
20 Oct 2025 //
PR NEWSWIRE
IDEAYA Reveals Phase 2 Data for Darovasertib in Uveal Melanoma
08 Sep 2025 //
PR NEWSWIRE
IDEAYA Reveals Ph 1/2 Trial Data of IDE397 & Trodelvy in Cancer
08 Sep 2025 //
PR NEWSWIRE
Ideaya Biosciences Joins September 2025 Investor Relations Events
25 Aug 2025 //
PR NEWSWIRE
IDEAYA, Hengrui to Present IDE849 (SHR-4849) Data at IASLC 2025
22 Jul 2025 //
PR NEWSWIRE
IDEAYA Biosciences Announces FDA IND-Clearance for IDE849
06 May 2025 //
PR NEWSWIRE
IDEAYA Biosciences Reports Q1 2025 Results and Business Update
06 May 2025 //
PR NEWSWIRE
IDEAYA Biosciences Expands IDE397 and Trodelvy Combo in MTAP-Dele
10 Apr 2025 //
PR NEWSWIRE
IDEAYA Bio gets FDA Breakthrough for Darovasertib in Uvea Melanoma
31 Mar 2025 //
PR NEWSWIRE
Ideaya, Attmos Partner On AI/ML Drug Discovery For Oncology
03 Mar 2025 //
PR NEWSWIRE
IDEAYA snags second ADC in tie-up with Hengrui worth $1B
30 Dec 2024 //
PRESS RELEASE
IDEAYA Biosciences Licenses SHR-4849 ADC for SCLC and NET Tumors
29 Dec 2024 //
PR NEWSWIRE
Ideaya Starts Phase 1 Trial For IDE161 With KEYTRUDA® In Cancer
10 Dec 2024 //
PR NEWSWIRE
IDEAYA Announces IDE034 Nomination for B7H3/PTK7 ADC
11 Nov 2024 //
PR NEWSWIRE
Biocytogen Announces IDEAYA’s Nomination of IDE034 Bispecific ADC
11 Nov 2024 //
BUSINESSWIRE
IDEAYA Announces ADC Program Agreement With Biocytogen
31 Jul 2024 //
PR NEWSWIRE
IDEAYA Biosciences Initiates Phase 1 Trial for IDE397 and Trodelvy® Combination
25 Jun 2024 //
PR NEWSWIRE
Ideaya announces results for darovasertib ph 2 IST in neoadjuvant uveal at ASCO
05 Jun 2024 //
PHARMABIZ
IDEAYA`s Darovasertib Uveal Melanoma, Neoadjuvant Data At ASCO
03 Jun 2024 //
PR NEWSWIRE
Ideaya Darovasertib Uveal Summary: Ph2 Neoadjuvant Asco Oral Presentation
23 May 2024 //
PR NEWSWIRE
IDEAYA`s Darovasertib Uveal Melanoma Data in ASCO Oral Session
24 Apr 2024 //
PR NEWSWIRE
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib
16 Oct 2023 //
PR NEWSWIRE
IDEAYA Announces First-Patient-In for Phase 2 Evaluating Darovasertib
16 Aug 2023 //
PRESS RELEASE
IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant
23 Jan 2023 //
PRESS RELEASE
